Acute Annular Outer Retinopathy

1. Disease Information

Overview

Acute Annular Outer Retinopathy (AAOR) is a rare inflammatory disease of the outer retina, classified within the white dot syndrome (WDS) family and the AZOOR complex. It was first described as a distinct entity by Fekrat et al. (2000), who reported four healthy patients who developed "acute onset of visual field loss associated with a localized, white annular outer retinopathy" (PMID: 11078842). AAOR is now considered a clinical variant of AZOOR, which was originally described by Gass in 1993 (PMID: 8340485).

Key Identifiers

Synonyms and Alternative Names

• Acute Annular Outer Retinopathy (AAOR) -- primary name
• Acute Outer Retinopathy (AOR) -- expanded spectrum term, proposed 2025
• AZOOR variant / AZOOR with annular pattern
• Annular variant of AZOOR
• Part of: AZOOR complex, White dot syndromes

Information Source

All information is derived primarily from aggregated disease-level resources (case reports and small case series). The largest published series includes 23 patients (Ramtohul et al. 2025, PMID: 40436146) and 9 patients (Chen et al. 2025, PMID: 40446848).

2. Etiology

Disease Causal Factors

The etiology of AAOR remains unknown (PMID: 30455116). The condition is considered to have a complex, non-genetic, likely autoimmune or post-infectious pathogenesis. Key etiological hypotheses include:

Autoimmune mechanism: Tagami et al. (2014) demonstrated that "AZOOR could be an autoimmune disease. All AZOOR patients tested using molecular biological methods had antiretinal antigens" (PMID: 25266678). Autologous antibodies targeting outer retinal photoreceptors were found in all 5 AZOOR patients studied. Shimazaki et al. (2008) also reported the association of antiretinal antibodies specifically in AAOR (PMID: 18195232).

Post-viral/post-infectious trigger: A preceding viral illness has been reported in several cases. Kitamura et al. (2018) described a 56-year-old man who "had fever one month and a half before presenting" and "noticed bilateral visual loss after lowering of fever" (PMID: 30079710). The original AZOOR description by Gass (1993) noted this association frequently (PMID: 8340485).

Possible paraneoplastic association: Gupta et al. (2022) reported the first case of AAOR in a patient with invasive ductal breast carcinoma, where "the patient presented with photopsias and visual loss approximately 3 weeks prior to a diagnosis of invasive ductal breast carcinoma" (PMID: 36434575).

Risk Factors

Genetic Risk Factors

• No genetic risk factors have been identified
• Roy & Dutta Majumder (2024) stated that AZOOR is "distinct from genetic disorders like retinitis pigmentosa, lacks a hereditary basis" (PMID: 38454854)
• No GWAS or candidate gene studies have been performed for AAOR

Environmental/Demographic Risk Factors

• Age: Young to middle-aged adults predominantly affected. Chen et al. (2025): ages 18-39 years (PMID: 40446848); Ramtohul et al. (2025): mean age 41.8 +/- 18.6 years, range 14-86 (PMID: 40436146)
• Sex: Female predominance. Monson & Smith (2011): male:female ratio 1:3.2 (PMID: 21056448). Ramtohul et al. (2025): 15 female, 8 male (1:1.875)
• Race/Ethnicity: Predominantly affects white/Caucasian individuals (PMID: 21056448)
• Preceding viral illness: Febrile illness preceding onset reported in multiple cases
• HIV infection: Garcia-Torre & Castro-Florez (2019) reported the first AAOR case in an HIV-positive patient (PMID: 30455116)
• Malignancy: Breast carcinoma reported in temporal association (PMID: 36434575)
• Epilepsy: An AZOOR case was reported in a patient with epilepsy, with the authors noting that "epileptic episodes contribute to an inflammatory response both in the brain and the retina" (PMID: 34833494)

Protective Factors

No genetic or environmental protective factors have been identified. This reflects the unknown etiology and extreme rarity of the condition.

Gene-Environment Interactions

Not characterized due to the absence of identified genetic risk factors and the extremely low prevalence of the disease. The disease appears to be entirely acquired rather than inherited.

3. Phenotypes

Symptoms and Clinical Signs

The largest multicenter study by Ramtohul et al. (2025) of 23 patients with AOR (38 eyes) quantified presenting symptoms: "photopsia (87%), blurred vision (57%), and scotoma (57%)" (PMID: 40436146).

1. Photopsia (Flashing/Flickering lights)

• Type: Symptom (visual)
• HPO term: HP:0030786 (Photopsia)
• Frequency: 87% of patients (PMID: 40436146); chronic photopsia reported in most patients
• Onset: Acute onset, typically the presenting symptom
• Severity: Variable; can be persistent
• Progression: Often chronic; Gass (1993) noted "most had chronic photopsia" (PMID: 8340485)
• QoL impact: Significant; disturbing visual phenomenon affecting daily activities

2. Visual Field Defects / Scotoma

• Type: Clinical sign / Symptom
• HPO terms: HP:0000572 (Visual field defect), HP:0000575 (Scotoma), HP:0001133 (Constriction of peripheral visual field)
• Frequency: 57% presented with scotoma (PMID: 40436146); blind spot enlargement in 75% of tested eyes (PMID: 21056448)
• Onset: Acute onset; progressive during the acute phase (1-3 weeks)
• Severity: Mild to severe; Gass (1993): "all had permanent visual field loss that in some cases was severe" (PMID: 8340485)
• Progression: Usually stabilizes within 6 months (PMID: 21056448), but long-term progressive atrophy possible over years (PMID: 23591538)
• QoL impact: Major; permanent scotomas affect reading, driving, and spatial navigation

3. Blurred Vision / Decreased Visual Acuity

• Type: Symptom
• HPO terms: HP:0000505 (Visual impairment), HP:0007663 (Reduced visual acuity)
• Frequency: 57% of patients (PMID: 40436146)
• Onset: Acute onset
• Severity: Highly variable depending on macular involvement. Chen et al. (2025): BCVA 20/20 without macular involvement vs. HM-20/400 with macular involvement (PMID: 40446848). Monson & Smith (2011): "Visual acuity was 20/40 or better in 74% of tested eyes" (PMID: 21056448)
• QoL impact: Ranges from minimal to devastating depending on macular involvement

4. Annular White Ring (Outer Retinal Whitening)

• Type: Clinical sign (ophthalmoscopic finding)
• HPO terms: HP:0007703 (Abnormality of retinal pigmentation) [late stage]
• Frequency: Defining feature of AAOR (100% during acute phase)
• Characteristics: Gray-white, peripapillary, annular band of deep retinal opacification (PMID: 11078842). Chen et al. (2025) noted "advancement of peripapillary annular band" during the acute progressive stage, which disappeared during the stationary stage (PMID: 40446848)
• Progression: Transient; resolves into depigmented areas with scattered pigmentation (atrophic stage)

5. Electroretinographic (ERG) Abnormalities

• Type: Laboratory abnormality (electrophysiology)
• HPO terms: HP:0000654 (Abnormal ERG), HP:0030464 (Abnormal full-field ERG)
• Frequency: 99% of AZOOR patients tested (PMID: 21056448)
• Characteristics: Reduced amplitudes, predominantly affecting rod-mediated responses in some cases (PMID: 19847620)
• Significance: Critical diagnostic marker; may be abnormal even with normal-appearing fundus

6. Fundus Autofluorescence Abnormalities

• Type: Clinical sign (imaging finding)
• HPO term: HP:0030624 (Abnormal fundus autofluorescence imaging)
• Frequency: Present in virtually all cases on imaging
• Characteristics: Hyperautofluorescent ring corresponding to advancing edge of disease; trizonal pattern (hyperautofluorescent, hypoautofluorescent, and normal zones) in chronic stage; ring-like hyperautofluorescent lesions surrounding optic disc in 18% of eyes (PMID: 40436146)

7. OCT Abnormalities (Ellipsoid Zone Disruption)

• Type: Clinical sign (imaging finding)
• HPO term: HP:0030329 (Retinal thinning)
• Frequency: Universal on OCT imaging
• Characteristics: Absent/disrupted ellipsoid zone (EZ), thinned outer nuclear layer (ONL), angular sign of Henle fiber layer hyperreflectivity (ASHH) (PMID: 40436146), hyperreflective foci in inner retina (PMID: 30079710), increased choroidal thickness acutely, decreased choroidal thickness in atrophic stage (PMID: 40446848)

8. Retinal Pigment Epithelium Changes (Late)

• Type: Clinical sign
• HPO terms: HP:0007703 (Abnormality of retinal pigmentation), HP:0000580 (Pigmentary retinopathy)
• Frequency: Common in late/atrophic stage
• Progression: Develops over months to years; Gass (1993): "most had... zones of pigment epithelial atrophy" (PMID: 8340485)

Summary of HPO Terms

4. Genetic/Molecular Information

Causal Genes

No causal genes have been identified for AAOR. Roy & Dutta Majumder (2024) explicitly stated the condition is "distinct from genetic disorders like retinitis pigmentosa, lacks a hereditary basis" (PMID: 38454854). Ramtohul et al. (2025) performed genetic testing as part of their evaluation but did not identify causal variants (PMID: 40436146).

Pathogenic Variants

Not applicable; AAOR is not a Mendelian genetic disorder.

Modifier Genes / Epigenetic Information / Chromosomal Abnormalities

None identified. No epigenetic studies or chromosomal analyses have been performed on AAOR.

Molecular Findings

The primary molecular finding is the presence of antiretinal antibodies in affected patients:

• Tagami et al. (2014) found autologous antibodies targeting outer retinal antigens in all 5 AZOOR patients tested. Immunohistochemical staining revealed the target antigen was present in all photoreceptors (PMID: 25266678)
• Shimazaki et al. (2008) reported antiretinal antibody association specifically in AAOR (PMID: 18195232)
• Related work on autoimmune retinopathy has identified recoverin, alpha-enolase, TULP1, and carbonic anhydrase II as retinal autoantigens (PMID: 40141211, PMID: 24428923), though these have not been specifically confirmed in AAOR

5. Environmental Information

Environmental Factors

No specific environmental toxins, radiation, pollution, or occupational exposures have been linked to AAOR.

Lifestyle Factors

No lifestyle factors (smoking, diet, exercise, alcohol consumption) have been identified as contributing factors.

Infectious Agents

Viral infections are suspected as potential triggers:

• Preceding febrile illness: Multiple cases report fever or viral prodrome weeks before onset
• HIV: First case of AAOR in an HIV-positive patient reported (PMID: 30455116), though "the precise role played by HIV infection or secondary immunosuppression in the development of the AAOR is not known"
• Coxsackievirus: In the related condition APMPPE, elevated Coxsackievirus B titers were found in 6 of 7 patients (PMID: 32834009), suggesting enteroviruses may serve as immune triggers in white dot syndromes more broadly
• No specific pathogen has been definitively identified as causative in AAOR

6. Mechanism / Pathophysiology

Overview of Pathogenic Cascade

The current understanding of AAOR pathophysiology, based primarily on multimodal imaging studies and autoantibody detection, is:

1. Trigger event (unknown; possibly viral infection or autoimmune activation)
2. Primary photoreceptor outer segment damage (autoimmune-mediated attack on photoreceptors)
3. Inflammatory phase with choroidal thickening and advancing annular lesion
4. Stabilization with partial recovery possible
5. Secondary RPE and choriocapillaris involvement during chronic atrophic phase

Molecular Pathways

No specific signaling pathways have been definitively implicated. Autoimmune/inflammatory signaling is suspected based on: - Antiretinal antibodies (PMID: 25266678) - Response to immunosuppressive therapy in some cases - Anti-TNF-alpha therapy (adalimumab) showing benefit in AZOOR overlap (PMID: 23765682)

Cellular Processes

Photoreceptor degeneration/apoptosis: The primary pathology. Herbort et al. (2021) established through multimodal imaging that "the primary damage was identified at the level of the photoreceptor outer segments with an intact choriocapillaris and retinal pigment epithelium (RPE) layer, these structures being only secondarily involved" (PMID: 34209956).

Seetharam et al. (2015) confirmed at the structural level: "hyperreflectivity in the outer nuclear layer and the Henle fiber layer along with marked atrophy of the outer retina within the white ring" (PMID: 25383859). Importantly, restoration of foveal photoreceptors correlated with visual recovery, supporting the photoreceptor as the critical target.

Relevant GO terms: GO:0006915 (apoptotic process), GO:0001895 (retinal homeostasis), GO:0007601 (visual perception)

Protein Dysfunction

Tagami et al. (2014) found that "the target antigen was present in all photoreceptors of the mouse sensory retina" when testing AZOOR patient sera. Candidate antigens were identified by mass spectrometry but not definitively characterized (PMID: 25266678). Related work on autoimmune retinopathy has identified recoverin, alpha-enolase, TULP1, and CRMP-5 as retinal autoantigens (PMID: 40141211, PMID: 24428923).

Immune System Involvement

Autoimmunity is the leading pathogenic hypothesis: - Antiretinal antibodies found in AZOOR/AAOR patients (PMID: 25266678, PMID: 18195232) - Female predominance (characteristic of autoimmune diseases) - Some response to immunosuppressive therapy - Post-infectious trigger consistent with molecular mimicry or immune dysregulation - Mouse models of recoverin-associated AIR demonstrate complement deposition (C1q, C3), CD4+ T cell and CD68+ macrophage infiltration (PMID: 21031137)

Suggested GO terms: GO:0006955 (immune response), GO:0002377 (immunoglobulin production), GO:0006958 (complement activation, classical pathway), GO:0006959 (humoral immune response)

Important Mechanistic Distinction

Herbort et al. (2021) critically distinguished AZOOR (including AAOR) from choriocapillaritis diseases (such as multifocal choroiditis, punctate inner choroidopathy), demonstrating that AZOOR "results from a clinicopathological mechanism different from choriocapillaritis diseases" (PMID: 34209956). In choriocapillaritis, the primary target is the choroidal vasculature; in AZOOR/AAOR, it is the photoreceptor layer.

Cell Types Involved

Molecular Profiling

No transcriptomic, proteomic, metabolomic, lipidomic, or epigenomic profiling studies have been performed specifically on AAOR tissue. This represents a major knowledge gap. No single-cell, spatial transcriptomic, or functional genomic screens have been conducted.

Proposed Causal Chain Diagram

TRIGGER PHASE
+-- Viral infection (febrile illness, HIV, unknown pathogen)
+-- Paraneoplastic stimulus (rare; breast carcinoma reported)
+-- Idiopathic immune activation
 |
 v
IMMUNE PHASE
+-- Molecular mimicry or antigen release
+-- Generation of antiretinal autoantibodies
|   +-- Target: photoreceptor outer segment antigens
+-- Complement activation (C1q, C3 deposition)
+-- Cellular immune infiltration (CD4+ T cells, CD68+ macrophages)
 |
 v
ACUTE PROGRESSIVE STAGE (1-3 weeks)
+-- Photoreceptor outer segment destruction (ellipsoid zone loss)
+-- Outer nuclear layer thinning
+-- Annular white ring visible on fundoscopy
+-- Increased choroidal thickness (inflammatory edema)
+-- Hyperautofluorescence at active margins
 |
 v
STATIONARY STAGE (3 weeks - 3 months)
+-- Resolution of annular band
+-- Partial ONL recovery possible
+-- Immune response waning
+-- Beginning of reparative processes
 |
 v
ATROPHIC STAGE (>3 months)
+-- RPE depigmentation and scattered pigmentation
+-- Permanent retinal atrophy
+-- Decreased choroidal thickness
+-- Risk of choroidal neovascularization
+-- Stable visual field defects

7. Anatomical Structures Affected

Organ Level

• Primary organ: Eye (specifically the retina)
• UBERON:0000966 (retina), UBERON:0000019 (camera-type eye)
• Body system: Visual/nervous system
• Laterality: Can be unilateral or bilateral. Mrejen et al. (2014): 18 of 30 AZOOR patients had bilateral lesions, mostly asymmetric (PMID: 24945598). Ramtohul et al. (2025): 38 eyes from 23 patients (bilateral in many) (PMID: 40436146)
• No secondary organ involvement: AAOR is confined to the eye

Tissue and Cell Level

Tissues affected (in order of involvement):

Cell populations affected: - Photoreceptor cells (rods and cones): Primary target -- CL:0000604 (retinal rod cell), CL:0000573 (retinal cone cell) - Retinal pigment epithelial cells: Secondary -- CL:0002586 - Yokoyama et al. (2009) noted "predominant loss of rod-mediated electroretinogram response," suggesting rods may be preferentially affected in some cases (PMID: 19847620)

Subcellular Level

• Photoreceptor outer segments: Site of primary damage -- GO:0001750 (photoreceptor outer segment)
• Ellipsoid zone (photoreceptor inner segment mitochondria): Disrupted on OCT -- GO:0001917 (photoreceptor inner segment)
• Interdigitation zone (RPE-photoreceptor interface): Indistinct on imaging (PMID: 30079710)

Localization

• Peripapillary region: The annular lesion typically originates around the optic disc (UBERON:0001783)
• Posterior pole/macula: May or may not be involved; macular involvement determines prognosis (UBERON:0000053, UBERON:0001785)
• Pattern: Annular (ring-shaped), expanding centrifugally from the optic disc
• Lateralization: Can be unilateral or bilateral, often asymmetric when bilateral

8. Temporal Development

Onset

• Typical age of onset: Young to middle-aged adults
• Chen et al. (2025): 18-39 years (PMID: 40446848)
• Ramtohul et al. (2025): mean 41.8 years (range 14-86) (PMID: 40436146)
• Monson & Smith (2011): average 36.7 years (PMID: 21056448)
• Fekrat et al. (2000): two patients aged 29/32 and two aged 71/79, suggesting possible bimodal distribution (PMID: 11078842)
• Onset pattern: Acute -- sudden onset of symptoms (photopsia, scotoma, visual loss)

Three-Stage Clinical Course

Chen et al. (2025) provided the first systematic staging of AAOR: "The clinical course was subdivided acutely progressive stage (APS), stationary stage (SS) and atrophic stage (AS) (1-3 weeks, 3 weeks to 3 months and >3 months, respectively)" (PMID: 40446848).

Progression

• Progression rate: Rapid during acute phase (1-3 weeks), then stabilizes
• Disease course: Monophasic in most cases; Monson & Smith (2011): "unusual for visual field loss to continue beyond six months" (PMID: 21056448)
• Disease duration: Self-limited acute phase; chronic permanent residual damage
• Long-term: Hoang et al. (2013) reported 13-year follow-up showing "chorioretinal atrophy progressed significantly" and that "the prognosis of cases with AZOOR should be cautiously considered" (PMID: 23591538)

Patterns

• Remission: The acute inflammatory phase is self-limited. Partial recovery of photoreceptor function can occur at the fovea; Seetharam et al. (2015) documented "restoration of foveal photoreceptors, which corresponded with visual recovery" (PMID: 25383859)
• Recurrence: Generally considered a monophasic disorder, but recurrent episodes are possible
• Critical period: The acute progressive stage (1-3 weeks) represents the window for potential therapeutic intervention

9. Inheritance and Population

Epidemiology

• Prevalence: Unknown; extremely rare. Only approximately 131 cases of AZOOR (including AAOR) were compiled in the English literature by 2011 (PMID: 21056448). AAOR specifically has fewer than 50 reported cases.
• Incidence: Not established; too rare for population-based estimates
• Classified as an ultra-rare disease

Genetic Inheritance

Not applicable: AAOR is not a hereditary disease. Roy & Dutta Majumder (2024): AZOOR "lacks a hereditary basis" (PMID: 38454854).

Population Demographics

10. Diagnostics

Clinical Tests

Ophthalmoscopy/Funduscopy

• Acute phase: Gray-white annular band of deep retinal opacification (defining feature of AAOR)
• Late phase: Depigmentation with scattered pigmentation, RPE atrophy
• In classic AZOOR, fundus may appear normal; AAOR is distinguished by visible fundus changes

Optical Coherence Tomography (OCT)

• Critical diagnostic tool
• Disrupted/absent ellipsoid zone (EZ), thinned outer nuclear layer (ONL), hyperreflectivity in ONL and Henle fiber layer
• Angular sign of Henle fiber layer hyperreflectivity (ASHH) (PMID: 40436146, PMID: 25383859)
• Increased choroidal thickness in acute phase; decreased in chronic phase (PMID: 40446848)
• Hyperreflective foci in inner retina and indistinct interdigitation zone even in ophthalmoscopically normal areas (PMID: 30079710)

Fundus Autofluorescence (FAF)

• Hyperautofluorescent ring at the advancing edge of disease
• Trizonal pattern in chronic stage: hyperautofluorescent, hypoautofluorescent, and normal zones (PMID: 24945598, PMID: 34833494)
• Ring-like hyperautofluorescent lesions surrounding the optic disc in 18% of eyes (PMID: 40436146)

OCT Angiography (OCTA)

• Enlarged foveal avascular zone, especially in atrophic stage (PMID: 40446848)
• Useful for detecting choriocapillaris changes and differentiating from choriocapillaritis diseases

Fluorescein Angiography (FA) / Indocyanine Green Angiography (ICGA)

• FA: Variable findings; may show transmission defects in areas of RPE atrophy
• ICGA: Can demonstrate choroidal involvement; helps differentiate from choriocapillaritis

Visual Field Testing

• Blind spot enlargement (75% of cases, PMID: 21056448)
• Scotomas corresponding to areas of photoreceptor damage
• Essential for documenting functional loss and monitoring progression

Electroretinography (ERG)

• Highly sensitive diagnostic test: abnormal in 99% of AZOOR patients tested (PMID: 21056448)
• Full-field ERG: Reduced amplitudes, particularly scotopic responses
• Multifocal ERG: Reduced amplitudes in areas corresponding to scotomas
• May show predominantly rod-mediated loss (PMID: 19847620)

Adaptive Optics Imaging

• Can reveal indistinct cone mosaic patterns in ophthalmoscopically normal areas (PMID: 30079710)

Biomarkers

• Antiretinal antibodies: Found in AZOOR patients (PMID: 25266678, PMID: 18195232); not yet validated as a clinical biomarker but may support diagnosis

Genetic Testing

• Not indicated for AAOR as it is not a genetic disease
• May be performed to exclude genetic mimics (e.g., retinitis pigmentosa) (PMID: 40436146)

Clinical Criteria

No formally standardized diagnostic criteria exist. Diagnosis is based on: 1. Acute onset of photopsia and/or scotoma 2. Visible annular white ring of outer retinal opacification on funduscopy (distinguishes from classic AZOOR) 3. OCT evidence of outer retinal damage (EZ disruption, ONL thinning) 4. ERG abnormalities 5. FAF changes (hyperautofluorescent margins, trizonal pattern) 6. Exclusion of other causes (syphilis, cancer-associated retinopathy, retinitis pigmentosa, toxic retinopathy, etc.)

Differential Diagnosis

11. Outcome/Prognosis

Visual Acuity Outcomes

The critical prognostic determinant is macular involvement:

• Chen et al. (2025): "Seven eyes of 5 patients showed no macular involvement with best corrected visual acuity (BCVA) of 20/20, while 5 eyes of 5 patients showed macular involvement with poorer BCVA of HM-20/400 at the last visit" (PMID: 40446848)
• Monson & Smith (2011): "Visual acuity was 20/40 or better in 74% of tested eyes" across the AZOOR/AAOR spectrum (PMID: 21056448)
• Ramtohul et al. (2025): mean follow-up 3.7 +/- 1.5 years (PMID: 40436146)

Visual Field Outcomes

• All patients have permanent visual field loss (PMID: 8340485)
• Typically stabilizes within 6 months (PMID: 21056448)
• Some patients may show progressive loss over years (PMID: 23591538)

Survival and Mortality

• AAOR does not affect survival or mortality
• Life expectancy is normal

Morbidity

• Visual field defects are permanent and can be disabling
• Central vision loss when macula is involved
• Chronic photopsia can affect quality of life

Complications

• Choroidal neovascularization (CNV): Introini et al. (2018) reported type 2 subretinal CNV as a complication of AZOOR, treatable with anti-VEGF (PMID: 30181904)
• Progressive chorioretinal atrophy: Long-term follow-up shows continued atrophic changes (PMID: 23591538)
• RPE disturbances: Commonly develop over time (PMID: 21056448)

Recovery Potential

• Foveal photoreceptor restoration possible in some cases; Seetharam et al. (2015): documented "restoration of foveal photoreceptors, which corresponded with visual recovery" (PMID: 25383859)
• However, peripheral photoreceptor loss is generally permanent

Prognostic Factors

12. Treatment

Overview

There is no proven effective treatment for AAOR. Monson & Smith (2011) concluded: "Various treatments have been attempted in patients with AZOOR--including systemic corticosteroids, other systemic immunosuppressive agents, and different antimicrobials--but none have been proven effective" (PMID: 21056448). All treatment evidence comes from case reports and small case series.

Pharmacotherapy

Surgical and Interventional

• No surgical interventions are indicated for primary AAOR
• Photodynamic therapy (PDT) used for CNV complication in one patient (PMID: 30181904)

Supportive and Rehabilitative Care

• Low vision aids for patients with significant visual field or acuity loss (MAXO:0001305)
• Regular monitoring with multimodal imaging to track progression
• Patient education and counseling (MAXO:0000540)

Treatment Strategy

• No standardized treatment algorithm exists
• Observation is reasonable given the self-limited acute phase
• Early immunosuppression may be considered during the acute progressive stage based on anecdotal evidence
• Treatment of complications (CNV) as they arise

Experimental Treatments

No active clinical trials specifically for AAOR are registered on ClinicalTrials.gov. The extreme rarity of the condition makes randomized controlled trials impractical.

13. Prevention

Primary Prevention

• Not possible given the unknown etiology
• No modifiable risk factors have been identified

Secondary Prevention (Early Detection)

• No screening programs exist
• High clinical suspicion is needed in young adults presenting with acute photopsia and scotoma
• Roy & Dutta Majumder (2024) emphasized "the necessity of high clinical suspicion and the role of advanced imaging in diagnosis and management" (PMID: 38454854)

Tertiary Prevention (Preventing Complications)

• Regular ophthalmologic follow-up to monitor for progressive atrophy, choroidal neovascularization (PMID: 30181904), and fellow eye involvement
• OCTA monitoring may detect early CNV development

Genetic Counseling

• Not indicated as the disease is not hereditary

14. Other Species / Natural Disease

Natural Disease in Animals

• No naturally occurring animal model of AAOR has been identified
• AZOOR/AAOR appears to be a uniquely human disease

Comparative Biology

Autoimmune retinopathies have been studied in animal models (mouse), but these model the broader concept of anti-retinal autoimmunity rather than AAOR specifically. Lu et al. (2010) created mouse models of recoverin-associated autoimmune retinopathy, demonstrating that anti-recoverin antibodies cause "significantly reduced scotopic and photopic responses on the ERGs" and "photoreceptor and outer nuclear layer swelling" (PMID: 21031137).

Zoonotic Potential

• Not applicable

15. Model Organisms

Available Models

No specific AAOR animal models exist. Related models include:

Autoimmune Retinopathy Mouse Models Detail

Lu et al. (2010, PMID: 21031137): - Recoverin-immunized LPR mice: B6.MRL-Fas(lpr)/J mice immunized with recombinant recoverin showed "swollen cell bodies in the inner nuclear layer," reduced ERG, and increased GFAP staining indicating Muller cell and astrocyte reactive gliosis - Recoverin hybridoma-injected Balb/cJ mice: "photoreceptor and outer nuclear layer swelling" with complement C1q and C3 deposits and "increased numbers of CD4+ and CD68+ cells from retinas" - Both models demonstrated "leukocyte invasion, complement deposition, reactive gliosis in the retina, and selective retinal degeneration"

Model Limitations

• No model reproduces the characteristic annular spreading pattern of AAOR
• Mouse retinal anatomy differs from human (no fovea, rod-dominant)
• The specific autoantigen(s) in AAOR remain unidentified, limiting targeted model development

Research Applications

Mouse autoimmune retinopathy models may be useful for: - Testing immunomodulatory therapies - Understanding photoreceptor autoimmune destruction mechanisms - Characterizing candidate retinal autoantigens

Key Findings Summary

Finding 1: AAOR is a distinct entity within the AZOOR spectrum

Fekrat et al. (2000) established AAOR as a specific clinical variant by describing four patients with "acute onset of visual field loss associated with a localized, white annular outer retinopathy" (PMID: 11078842). Monson & Smith (2011) subsequently compiled 131 AZOOR cases including AAOR, confirming: "predominantly white individuals, average age at presentation was 36.7 years, and the male:female ratio was 1:3.2" (PMID: 21056448). Chen et al. (2025) reported 9 AAOR patients (12 eyes) aged 18-39 years (PMID: 40446848), and Ramtohul et al. (2025) expanded the concept to 23 patients under "Acute Outer Retinopathy" (PMID: 40436146).

Finding 2: Three-stage clinical course

Chen et al. (2025) provided the first systematic staging: "The clinical course was subdivided acutely progressive stage (APS), stationary stage (SS) and atrophic stage (AS) (1-3 weeks, 3 weeks to 3 months and >3 months, respectively)" (PMID: 40446848). This staging framework enables clinicians to anticipate disease evolution and time interventions.

Finding 3: Symptom frequencies quantified

Ramtohul et al. (2025) provided the most robust data: "Presenting symptoms included photopsia (87%), blurred vision (57%), and scotoma (57%)" from 23 patients. They also identified the "angular sign of Henle fiber layer hyperreflectivity (ASHH)" as an important OCT biomarker (PMID: 40436146).

Finding 4: Photoreceptor outer segment damage is the primary pathology

Herbort et al. (2021) established that "the primary damage was identified at the level of the photoreceptor outer segments with an intact choriocapillaris and retinal pigment epithelium (RPE) layer, these structures being only secondarily involved" (PMID: 34209956). Tagami et al. (2014) demonstrated autoantibodies targeting photoreceptors (PMID: 25266678). Seetharam et al. (2015) confirmed "hyperreflectivity in the outer nuclear layer and the Henle fiber layer along with marked atrophy of the outer retina within the white ring" (PMID: 25383859).

Finding 5: Visual prognosis depends on macular involvement; no proven treatment

Chen et al. (2025): "Seven eyes of 5 patients showed no macular involvement with best corrected visual acuity (BCVA) of 20/20, while 5 eyes of 5 patients showed macular involvement with poorer BCVA of HM-20/400" (PMID: 40446848). Monson & Smith (2011): "Various treatments have been attempted in patients with AZOOR--including systemic corticosteroids, other systemic immunosuppressive agents, and different antimicrobials--but none have been proven effective" (PMID: 21056448). Bemme et al. (2016) reported anecdotal success: "further progression could be stopped by a combination of antiviral and immunosuppressive therapy" (PMID: 25930180).

Evidence Base

Landmark Papers

Limitations and Knowledge Gaps

1. Extremely small sample sizes: The largest AAOR-specific study includes only 23 patients. All evidence is Level 4 (case series) or Level 5 (case reports).

2. No molecular characterization of target antigens: The specific photoreceptor antigens targeted by autoantibodies in AAOR remain unidentified.

3. No genetic studies: No GWAS, exome sequencing, or candidate gene studies have been performed. HLA typing has not been systematically reported.

4. No controlled treatment trials: The extreme rarity precludes randomized controlled trials. All treatment evidence is anecdotal.

5. No tissue pathology: No histopathological or immunohistochemical analysis of AAOR retinal tissue has been published. All structural understanding derives from in vivo imaging.

6. Inconsistent nomenclature: The relationship between AAOR, AOR, AZOOR, and MORR remains debated, complicating literature synthesis.

7. No standardized diagnostic criteria: Diagnosis remains clinical and exclusionary, without formally validated criteria.

8. No biomarkers for prognosis: Beyond macular involvement on imaging, no molecular or imaging biomarkers predict which patients will progress.

9. Absence of formal QoL studies: No patient-reported outcome measures have been assessed.

10. No animal model specific to AAOR: Existing autoimmune retinopathy models do not recapitulate the annular spatial pattern.

Proposed Follow-up Experiments/Actions

High Priority

1. Characterization of target autoantigens: Perform immunoprecipitation and mass spectrometry on sera from AAOR patients against retinal protein extracts to identify the specific photoreceptor antigens targeted.

2. HLA typing study: Collect HLA data from AAOR patients to identify susceptibility alleles, as done for other autoimmune ocular conditions (e.g., HLA-A29 in birdshot chorioretinopathy).

3. International registry: Establish a multicenter AAOR/AOR registry to accumulate sufficient patients for epidemiological and genetic analyses.

4. Standardized diagnostic criteria: Develop and validate formal diagnostic criteria using Delphi consensus methodology among retina specialists.

Medium Priority

1. Longitudinal imaging biomarker study: Correlate baseline multimodal imaging features (FAF patterns, choroidal thickness, ellipsoid zone disruption extent) with long-term visual outcomes to develop prognostic biomarkers.

2. Aqueous humor proteomics: Analyze aqueous humor samples from AAOR patients for cytokine profiles and antibody characterization.

3. Pilot treatment study: Design a prospective, multicenter observational study comparing early immunosuppression versus observation, given the impossibility of a RCT.

Lower Priority

1. Development of AAOR-specific animal model: Once target antigens are identified, immunize animal models with specific antigens to create a more faithful disease model.

2. Single-cell transcriptomics: If surgical biopsy becomes available, perform single-cell RNA sequencing to characterize the immune cell populations infiltrating affected retina.

3. Viral metagenomic analysis: Perform metagenomic sequencing on aqueous/vitreous samples during acute phase to identify potential viral triggers.

Ontology Term Summary

Key References

1. Gass JDM. Acute zonal occult outer retinopathy. 1993. PMID: 8340485
2. Fekrat S, et al. Acute annular outer retinopathy: report of four cases. 2000. PMID: 11078842
3. Monson DM, Smith JR. Acute zonal occult outer retinopathy. 2011. PMID: 21056448
4. Mrejen S, et al. Acute zonal occult outer retinopathy: a classification based on multimodal imaging. 2014. PMID: 24945598
5. Tagami M, et al. Autologous antibodies to outer retina in acute zonal occult outer retinopathy. 2014. PMID: 25266678
6. Seetharam SD, et al. New insights into acute annular outer retinopathy. 2015. PMID: 25383859
7. Bemme S, et al. Progressive scotoma with perception of photopsia. 2016. PMID: 25930180
8. Herbort CP, et al. AZOOR Results from a Clinicopathological Mechanism Different from Choriocapillaritis Diseases. 2021. PMID: 34209956
9. Hoang QV, et al. Long-term follow-up of acute zonal occult outer retinopathy. 2013. PMID: 23591538
10. Roy R, Dutta Majumder P. Current understanding of acute zonal occult outer retinopathy. 2024. PMID: 38454854
11. Chen B, et al. Acute annular outer retinopathy: initial insights into clinical course variations with multimodal imaging. 2025. PMID: 40446848
12. Ramtohul P, et al. Clinical and Multimodal Imaging of Acute Outer Retinopathy. 2025. PMID: 40436146
13. Gupta V, et al. Acute annular outer retinopathy preceded by invasive ductal breast carcinoma. 2022. PMID: 36434575
14. Garcia-Torre A, Castro-Florez M. AAOR associated with HIV. 2019. PMID: 30455116
15. Introini U, et al. Clinical course of AZOOR complicated by choroidal neovascularization. 2018. PMID: 30181904
16. Neri P, et al. Successful treatment of overlapping choriocapillaritis with adalimumab. 2014. PMID: 23765682
17. Lu L, et al. Two mouse models for recoverin-associated autoimmune retinopathy. 2010. PMID: 21031137

Report generated: 2026-05-05 | Based on review of 49 publications | 5 confirmed findings